Ashli Mullins
Family · Hazard, KYNPI 1427525377
Payments from drug & device makers
Across 140 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$379
- AbbVie$256
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$232
- Otsuka America Pharmaceutical, Inc.$214
- Lundbeck LLC$200
- Takeda Pharmaceuticals U.S.A., Inc.$183
- plus $998 from 22 others
What the payments were for
- Consulting fees$1155%
- Food & beverage$2,34695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$115
How this compares
$2,461 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 27 | $53,181 |
| Invega SustennaPaliperidone Palmitate | 18 | $49,339 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $6,447 |
| Buspirone Hcl | 109 | $829 |
| Trazodone Hcl | 85 | $734 |
| Quetiapine Fumarate | 73 | $563 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $496 |
| Hydroxyzine Pamoate | 51 | $433 |
| Fluvoxamine Maleate | 11 | $417 |
| Duloxetine Hcl | 20 | $375 |
| Clonazepam | 77 | $367 |
| Haloperidol | 21 | $358 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 43 | $328 |
| Ziprasidone Hcl | 13 | $277 |
| Divalproex Sodium | 30 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $214 | $53,18127 claims |
| Johnson & JohnsonInvega Sustenna | $379 | $49,33918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $183 | $6,44718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Hazard
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.